In Vitro Diagnostics Strategy

Based on the scientific and commercial success of its proteomic biomarker discovery and validation technology and services business, Caprion launched (in 2009) an initiative to discover and develop an internal pipeline of in-vitro diagnostic product candidates.

Caprion has so far secured over $25 million in funding from government contracts and industry partners in support of this initiative, and is actively pursuing development of a diversified pipeline of innovative in-vitro diagnostic product candidates in the areas of:

• infectious diseases
• oncology
• diabetes

Caprion’s diagnostic initiatives are focused on programs that leverage and enhance Caprion’s existing core proteomics competencies for biomarker discovery in tissues (secretory vesicles) and plasma with the use of multiplexed MRM assays for rapid biomarker verification and validation.

Caprion diagnostic programs are conducted in collaboration with leading academic and industrial partners that bring to the partnership world-leading disease area expertise and access to high quality well-characterized biological specimens collected from relevant clinical study cohorts.